Lantern Pharma Stock Quote LTRN - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

5.49

Bid

5.42

Ask

5.64

Volume

137,627

5.2675 Day's Range 5.595

2.38 52 Week Range 11.99

Market Cap

59.128M

Previous Close

5.39

Open

5.58

Last Trade

5.63

Last Trade Time

17:15:11

Financial Volume

$ 737,611

VWAP

5.3595

Average Volume (3m)

348,456

Shares Outstanding

10,869,040

Dividend Yield

PE Ratio

-3.70

Earnings Per Share (EPS)

-1.47

Revenue

Net Profit

-15.96M

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Wilmington, Delaware, USA

Founded

1970

Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was $5.39. Over the last year, Lantern Pharma shares have traded in a share price range of $ 2.38 to $ 11.99.

Lantern Pharma currently has 10,869,040 shares outstanding. The market capitalization of Lantern Pharma is $59.13 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -3.70.

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Q1 2024 Earnings Results & Corporate Updates Webcast to be held Thursday, May 9th, 4:30 p.m. ET, register for webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN...

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first webinar on the increasing prevalence of non-small...

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer...

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug...

Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks

In Monday’s pre-market trading, U.S. index futures are mixed, with Wall Street in anticipation of the monetary policy guidelines that the Federal Reserve is expected to release during the...

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

LP-284 is in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and other...

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company...

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern. Lantern’s CEO & President, Mr. Panna Sharma will be interviewed in the form of a fireside chat by HCW’s...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.11	2.04460966543	5.38	6.04	4.8901	152390	5.2051071	CS
4	-3.15	-36.4583333333	8.64	8.8999	4.8901	205798	6.38029391	CS
12	1.22	28.5714285714	4.27	11.99	3.85	348456	7.30749568	CS
26	2.93	114.453125	2.56	11.99	2.53	186226	6.88401698	CS
52	0.49	9.8	5	11.99	2.38	109744	6.54272634	CS
156	-9.8	-64.0941792021	15.29	16.5	2.38	70723	7.55747023	CS
260	-9.67	-63.7862796834	15.16	24.84	2.38	76539	10.16225842	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VAXXVaxxinity Inc	$ 0.1369 (31.38%)	5.23M
OLBOLB Group Inc	$ 0.5969 (21.92%)	689.54k
OSPNOneSpan Inc	$ 13.11 (19.73%)	37.14k
UPLDUpland Software Inc	$ 2.40 (18.81%)	11.74k
AXTIAXT Inc	$ 3.58 (18.15%)	77.7k
SPTSprout Social Inc	$ 38.00 (-21.08%)	174.69k
MRINMarin Software Incorporated	$ 2.58 (-18.10%)	92.15k
GVVisionary Holdings Inc	$ 0.2103 (-15.88%)	46.19k
WRNTWarrantee Inc	$ 0.2701 (-14.95%)	615.24k
AAONAAON Inc	$ 80.00 (-11.98%)	10.95k
AAPLApple Inc	$ 184.33 (6.53%)	20.58M
JAGXJaguar Health Inc	$ 0.3133 (6.86%)	8.06M
VAXXVaxxinity Inc	$ 0.1369 (31.38%)	5.23M
SQQQProShares UltraPro Short QQQ	$ 11.61 (-1.44%)	4.17M
FFIEFaraday Future Intelligent Electric Inc	$ 0.041 (2.24%)	3.46M